Centre for Energy Research, Hungarian Academy of Sciences, Konkoly-Thege Miklós út 29-33, 1121, Budapest, Hungary.
Chippenham Research Centre, Chiesi Limited, Chippenham, Wiltshire, SN14 0AB, UK.
Int J Pharm. 2017 Nov 25;533(1):225-235. doi: 10.1016/j.ijpharm.2017.09.057. Epub 2017 Sep 21.
The breath-actuated mechanism (BAM) is a mechanical unit included in NEXThaler with the role of delaying the emission of the drug until the inhalation flow rate of the patient is sufficiently high to detach the drug particles from their carriers. The main objective of this work was to analyse the effect of the presence of BAM on the size distribution of the emitted drug and its airway deposition efficiency and distribution. Study of the hygroscopic growth of the emitted drug particles and its effect on the deposition was another goal of this study. Size distributions of Foster NEXThaler drug particles emitted by dry powder inhalers with and without BAM have been measured by a Next Generation Impactor. Three characteristic inhalation profiles of asthmatic patients (low, moderate and high flow rates) were used for both experimental and modelling purposes. Particle hygroscopic growth was determined by a new method, where experimental measurements are combined with simulations. Upper airway and lung deposition fractions were computed assuming 5s and 10s breath-hold times. By the inclusion of BAM the fine particle fraction of the steroid component increased from 24 to 30% to 47-51%, while that of bronchodilator from 25-34% to 52-55%. The predicted upper airway steroid and bronchodilator doses decreased from about 60% to 35-40% due to BAM. At the same time, predicted lung doses increased from about 20%-35% (steroid) and from 22% to 38% (bronchodilator) for the moderate flow profile and from about 25% to 40% (steroid) and from 29% to 47% (bronchodilator) for the high inhalation flow profile. Although BDP and FF upper airway doses decreased by a factor of about two when BAM was present, lung doses of both components were about the same in the BAM and no-BAM configurations at the weakest flow profile. However, lung dose increased by 2-3% even for this profile when hygroscopic growth was taken into account. In conclusion, the NEXThaler BAM mechanism is a unique feature enabling high emitted fine particle fraction and enhanced drug delivery to the lungs.
呼气驱动装置(BAM)是 NEXThaler 中的一个机械单元,其作用是延迟药物的释放,直到患者的吸气流量足够高,以使药物颗粒从载体上脱离。这项工作的主要目的是分析 BAM 的存在对发射药物的粒径分布及其气道沉积效率和分布的影响。研究发射药物颗粒的吸湿性增长及其对沉积的影响是这项研究的另一个目标。通过下一代撞击器测量了带有和不带有 BAM 的 Foster NEXThaler 干粉吸入器发射的药物颗粒的大小分布。使用了三种哮喘患者的特征性吸气轮廓(低、中、高流量)进行实验和模拟。通过一种新方法确定了颗粒的吸湿性增长,该方法将实验测量与模拟相结合。假设呼吸暂停时间为 5s 和 10s,计算了上呼吸道和肺部的沉积分数。通过包含 BAM,类固醇成分的细颗粒分数从 24%增加到 30%至 47-51%,而支气管扩张剂的细颗粒分数从 25-34%增加到 52-55%。由于 BAM 的存在,预测的上呼吸道类固醇和支气管扩张剂剂量从约 60%减少到 35-40%。与此同时,预测的肺部剂量对于中流量分布,从约 20%-35%(类固醇)和 22%增加到 38%(支气管扩张剂),从约 25%增加到 40%(类固醇)和 29%增加到 47%(支气管扩张剂)对于高吸入流量分布。尽管当存在 BAM 时,BDP 和 FF 的上呼吸道剂量减少了约两倍,但在最弱的流量分布中,两种成分的肺部剂量在 BAM 和无 BAM 配置中是相同的。然而,当考虑吸湿性增长时,即使对于这个分布,肺部剂量也增加了 2-3%。总之,NEXThaler BAM 机制是一个独特的特征,能够实现高发射的细颗粒分数和增强的肺部药物输送。